These findings highlight the significance of NRG1 signaling in oncogenic processes and suggest that targeting the NRG1 pathway, alone or in combination with MEK1/2 or ADAM17 inhibition, may represent a promising therapeutic strategy for cancers with KRAS mutations and NRG1 alterations. Here, NRG1 is linked to cancer.